[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645365":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":30,"collaborators":7,"id":32,"slug":7,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":53,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Geneplus-Beijing Co. Ltd.","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Fei Ma, MD","CONTACT","+8615010127581","drmafei@126.com",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing","100100","China",{"type":21,"coordinates":22},"Point",[23,24],116.39723,39.9075,{"lat":24,"lon":23},[27,28],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":29,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":31,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100645365",false,"NCT07681323","Timing of ctDNA Testing in HR+\u002FHER2- Advanced Breast Cancer","Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)","TIMING","Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer, molecular subtype HR+\u002FHER2-\n* Age ≥18 years\n* Expected survival \\>3 months\n* Willing to undergo ctDNA testing and sign informed consent form\n\nExclusion Criteria:\n\n* The subject has not signed the informed consent form.\n* Pregnant or breastfeeding women.\n* Other situations deemed by the investigator as unsuitable for inclusion in the study.","ALL","18 Years",{"count":42,"type":43},400,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective observational cohort study aims to investigate the impact of ctDNA level and key actionable gene mutation status on prognosis and treatment response in patients with advanced HR+\u002FHER2- breast cancer.",[47],"Advanced Breast Cancer",[49,50,51,52],"ctDNA","multigene testing","HR+\u002FHER2- breast cancer","treatment strategy","NOT_YET_RECRUITING","2026-06-26",{"date":56,"type":57},"2026-07-02","ACTUAL",{"date":59,"type":43},"2026-06-30",{"date":61,"type":43},"2029-06-30",{"name":5,"class":6},1]